VYNE Therapeutics (VYNE) Free Cash Flow (2017 - 2026)
VYNE Therapeutics (VYNE) posted Free Cash Flow of -$4.1 million for Q1 2026, up 62.35% on a QoQ basis from -$10.8 million in Q2 2025, and up 64.39% year-over-year from -$2.5 million in Q1 2025.
VYNE Therapeutics (VYNE) Free Cash Flow (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$4.1 million for Q1 2026.
- Quarterly Free Cash Flow rose 64.39% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.4 million (up 29.56% YoY) and the FY2025 annual result came in at -$33.1 million, up 2.83% from the prior year.
- Free Cash Flow was -$4.1 million for Q1 2026 at VYNE Therapeutics, up from -$10.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4.1 million in Q1 2026 and bottomed at -$11.5 million in Q1 2025.
- A 5-year average of -$7.7 million and a median of -$8.2 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 75.18% — and 2026, when it soared 64.39%.
- VYNE Therapeutics' Free Cash Flow stood at -$4.8 million in 2022, then decreased by 6.78% to -$5.1 million in 2023, then sank by 75.18% to -$9.0 million in 2024, then retreated by 20.45% to -$10.8 million in 2025, then jumped by 62.35% to -$4.1 million in 2026.
- Business Quant data shows VYNE's Free Cash Flow at -$4.1 million in Q1 2026, -$10.8 million in Q2 2025, and -$11.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.95 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.08 Mn |
| Mar 31, 2026 | -4.08 Mn |
| Jun 30, 2025 | -10.84 Mn |
| Jun 30, 2025 | -10.84 Mn |
| Mar 31, 2025 | -11.46 Mn |
| Mar 31, 2025 | -11.46 Mn |
| Dec 31, 2024 | -9.00 Mn |
| Dec 31, 2024 | -9.00 Mn |
| Sep 30, 2024 | -8.51 Mn |
| Sep 30, 2024 | -8.51 Mn |
| Jun 30, 2024 | -8.48 Mn |
| Jun 30, 2024 | -8.48 Mn |
| Mar 31, 2024 | -7.98 Mn |
| Mar 31, 2024 | -7.98 Mn |
| Dec 31, 2023 | -5.14 Mn |
| Dec 31, 2023 | -5.14 Mn |
| Sep 30, 2023 | -5.15 Mn |
| Sep 30, 2023 | -5.15 Mn |
| Jun 30, 2023 | -9.57 Mn |
| Jun 30, 2023 | -9.57 Mn |